sub:assertion {
<http://purl.obolibrary.org/obo/DOID_7147> bl:categorybl:Disease . sub:associationrdf:object <http://purl.obolibrary.org/obo/DOID_7147> ; rdf:predicatebl:treats ; rdf:subject <https://identifiers.org/drugbank:DB06674> ; ardf:Statement ; rdfs:label "simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 1 1 active psoriatic arthritis psa alone or in combination with methotrexate 1 2 active ankylosing spondylitis as 1 3 moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 1 4 inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders simponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis simponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritis simponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6 mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 14 4" ; bl:association_typebl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ; bl:provided_by <https://w3id.org/um/NeuroDKG> ; bl:relationschema:TreatmentIndication .
<https://identifiers.org/drugbank:DB06674> bl:categorybl:Drug . }